WO2020050429A1 - Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine - Google Patents

Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine Download PDF

Info

Publication number
WO2020050429A1
WO2020050429A1 PCT/KR2018/010237 KR2018010237W WO2020050429A1 WO 2020050429 A1 WO2020050429 A1 WO 2020050429A1 KR 2018010237 W KR2018010237 W KR 2018010237W WO 2020050429 A1 WO2020050429 A1 WO 2020050429A1
Authority
WO
WIPO (PCT)
Prior art keywords
adiponectin
sensitive skin
peptide
seq
present
Prior art date
Application number
PCT/KR2018/010237
Other languages
English (en)
Korean (ko)
Inventor
정진호
김은주
이동훈
김연경
김지은
Original Assignee
주식회사 정진호이펙트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 정진호이펙트 filed Critical 주식회사 정진호이펙트
Priority to PCT/KR2018/010237 priority Critical patent/WO2020050429A1/fr
Publication of WO2020050429A1 publication Critical patent/WO2020050429A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition for sensitive skin comprising a peptide fragment (small peptide) derived from adiponectin.
  • Sensitive skin refers to skin that is more sensitive to external irritants, allergic substances, or environmental changes or internal causes of the body than normal skin, which causes irritation or dermatitis. These sensitive skin holders are on the increase. Some even claim that over half of all women in the United States are sensitive skin. Recently, interest in and skin science of sensitive skin has been increasing, but there is no method for alleviating or treating sensitive skin symptoms.
  • Adverse reactions on sensitive skin may follow inflammatory pathways such as contact irritation and allergic reactions. Since various inflammatory mediators (leukotrien, prostaglandin) and cytokines are involved in the reverse reaction, adverse reactions can be mitigated or diluted by the regulation of cytokines and inflammatory mediators.
  • adiponectin is a type of adipocaine, a protein hormone specifically secreted by fat cells. It improves insulin function and induces insulin resistance, thereby regulating cardiovascular diseases such as hyperglycemia, hyperinsulinemia, obesity, and atherosclerosis. Plays an important role in adiponectin has a function of suppressing metastasis and inflammatory reactions of cancer cells. Adiponectin not only promotes keratinocyte proliferation, but also promotes the expression of filarggrin, hyaluronic acid and extracellular matrix in the skin, thereby performing functions such as wound healing, suppressing fibrosis, improving skin wrinkles, and moisturizing (Korea) Published Patent Publication No. 10-2015-0032401).
  • Adiponectin consists of 244 amino acids and consists of a signal sequence, a collagen-like domain located at the N-terminal and a C1q-like globular domain located at the C-terminus.
  • the hexamer and the 400 kDa polymer complex are the major oligomers, and the polymer complex is known to have higher activity than the low molecular complex (LMW complex).
  • adiponectin-derived peptides which have been known to have various physiological activities, has been the target of many researchers and pharmaceutical companies at home and abroad, but the possibility of final success is relatively low due to difficulty in forming polymers in the body. Therefore, there is a need to develop a short peptide derived from adiponectin that can be applied to the skin and has excellent physiological activity.
  • An object of the present invention is to provide a composition for sensitive skin containing adiponectin-derived peptide.
  • the present invention provides a cosmetic composition or pharmaceutical composition for sensitive skin containing at least one of adiponectin-derived peptides selected from the group consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21 as an active ingredient.
  • the composition of the present invention preferably contains at least one of adiponectin derived peptides selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO: 21, but is not limited thereto.
  • the adiponectin-derived peptide may be contained in a cosmetic composition or pharmaceutical composition in a concentration of 0.001 to 20 mM, but is not limited thereto.
  • the cosmetic composition may be selected from, but is not limited to, a lotion, essence, lotion, cream, pack, gel, ointment, patch or spray formulation.
  • the present invention is a sensitized skin symptom comprising the step of treating or administering to a subject at least one of adiponectin derived peptides selected from the group consisting of a pharmaceutical or cosmetically effective amount of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21.
  • adiponectin derived peptides selected from the group consisting of a pharmaceutical or cosmetically effective amount of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21.
  • the individual may be a human, but is not limited thereto.
  • the present invention relates to a composition comprising an adiponectin-derived peptide having a relaxing effect on sensitive skin, wherein the adiponectin-derived peptide activates a downstream signaling pathway of the adiponectin receptor in muscle cells involved in a major etiology of sensitive skin, and Since it inhibits the activity of stimulating receptors induced by sensitive skin-causing substances, the composition comprising the adiponectin-derived peptide can be effectively used to suppress or alleviate sensitive skin symptoms.
  • FIG. 1 is a photograph showing the skin permeability test results of the peptide derived from adiponectin of the present invention.
  • FIG. 2A to 2C show the effects of the adiponectin-derived peptides of the present invention on the increased activity of PPARR ⁇ and PPAR ⁇ corresponding to the sub-signaling pathway of the adiponectin receptor (FIGS. 2A and 2B) and phosphorylation of AMPK and ACC (FIG. 2C). It is a graph showing and electrophoresis pictures.
  • FIG. 3 is a graph showing the effect of the adiponectin-derived peptide of the present invention on the expression of ASIC3, TRPV1 and CGRP genes, skin-sensitization-related genes induced by lactic acid.
  • Figure 4 shows the crystal structure for the structural position of the adiponectin peptide present in the adiponectin protein of the present invention.
  • the present invention provides a cosmetic composition or pharmaceutical composition for sensitive skin containing at least one of adiponectin derived peptides selected from the group consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21 as an active ingredient.
  • the peptide derived from adiponectin of the present invention is a peptide fragment having a length of 4 amino acids (4-mer) or 5 amino acids (5-mer) derived from adiponectin, and has an amino acid sequence shown in Table 1 below.
  • the adiponectin-derived peptide is preferably contained in a concentration of 0.001 to 20 mM in the cosmetic composition, more preferably contained in a concentration of 0.01 to 10 mM, but is not limited thereto.
  • concentration of the peptide is less than 0.001 mM, it is difficult to obtain a relieving effect on sensitive skin, and when it exceeds 20 mM, there is no obvious increase in effect due to an increase in the content, resulting in poor production economics.
  • Synthetic for example, can be prepared by solid-phase peptide synthesis (solid-phase peptide synthesis), the microorganism is transformed with a recombinant vector containing a nucleic acid encoding the peptide to express the peptide by culturing the microorganism, and then It may be purified by the method of, but is not limited thereto.
  • the cosmetic composition according to the present invention may contain, in addition to the above peptides, other ingredients that can give a synergistic effect to the effects of the peptides, within a range that does not impair the desired effect of the present invention.
  • the cosmetic composition of the present invention can be used as a conventional adjuvant, such as antioxidant, stabilizer, solubilizer, vitamin, pigment, and fragrance, as well as any other substances that have a known emollient effect on sensitive skin, or carriers. It can contain.
  • the cosmetic composition of the present invention is not particularly limited in its formulation, and may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions , Powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, and the like.
  • scalp treatments, soaps, hair tonics, shampoos, conditioners, hair packs, hair gels, lotions, conditioners, hair oils, mousses, creams, solids, solutions, emulsions, dispersants, micelles, liposomes, ointments It can also be prepared in the form of a lotion, essence, patch or spray.
  • the formulation of the cosmetic composition is a paste, cream or gel
  • animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, especially in the case of a spray, additionally chlorofluorohydrocarbon, propane / And propellants such as butane or dimethyl ether.
  • a solvent, solubilizing agent or emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
  • liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspensions such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Cellulose, aluminum metahydroxide, bentonite, agar or trakant can be used, and in the case of surfactant-containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, Imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol
  • the adiponectin-derived peptide of the present invention has a remarkably excellent permeability to the skin (see FIG. 1), and increases the activity of proteins in the lower signaling pathway through activation of adiponectin receptors in human-derived cell lines. Can be induced (see FIGS. 2A to 2C).
  • the adiponectin-derived peptide of the present invention can significantly inhibit the expression of genes related to skin sensitivity caused by lactic acid in human-derived cells (see FIG. 3).
  • composition comprising the adiponectin-derived peptide of the present invention can be usefully used as an active ingredient of a cosmetic composition for alleviating or suppressing sensitive skin symptoms.
  • the route of administration of the pharmaceutical composition for sensitive skin includes skin, oral cavity, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal, oral Or parenteral administration is preferred, but is not limited thereto.
  • the 'parenteral' includes subcutaneous, intradermal, intravenous, intramuscular, intralesional injection or infusion techniques.
  • the pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar function to the adiponectin derived peptide according to the present invention.
  • the composition may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method.
  • Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills, and the like.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include external preparations and sterile injections such as powders, granules, tablets, capsules, sterilized aqueous solutions, liquids, non-aqueous solvents, suspensions, emulsions, syrups, suppositories, aerosols, etc.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • composition may further contain preservatives, stabilizers, hydration or emulsification accelerators, adjuvants such as salts and / or buffers for osmotic pressure control, and other therapeutically useful substances, which are conventional methods of mixing, granulating or It can be formulated according to the coating method.
  • the pharmaceutical composition of the present invention can be variously changed according to various factors including the age, weight, general health, sex, administration time, administration route, discharge rate, drug combination, and severity of a specific disease.
  • a pharmaceutical composition containing the adiponectin-derived peptide of the present invention as an active ingredient is formulated in a unit dose form, it is preferable to contain the adiponectin-derived peptide in a unit dose of about 0.01 to 1,500 mg as an active ingredient, and for adults
  • the dosage required for treatment is usually, but not limited to, about 1 to 500 mg per day depending on the frequency and intensity of administration.
  • a single dose usually would be sufficient for a total dose of about 5 to 300 mg per day, but for some patients a higher daily dose may be desirable.
  • the composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormonal therapy, chemotherapy, and biological response modifiers.
  • the present invention is a sensitized skin symptom comprising the step of treating or administering to a subject at least one of adiponectin derived peptides selected from the group consisting of a pharmaceutical or cosmetically effective amount of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21.
  • adiponectin derived peptides selected from the group consisting of a pharmaceutical or cosmetically effective amount of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21.
  • the pharmaceutically or cosmetically effective amount is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, but is not limited thereto.
  • the treatment or dosage may be adjusted according to the weight, age, sex, health status, diet, administration period, administration method, elimination rate, disease severity, etc. of a specific patient. Treatment or administration may be administered once a day, or may be carried out in several times.
  • the individual is a vertebrate, preferably a mammal, more preferably a human or a laboratory animal such as a rat, rabbit, guinea pig, hamster, dog, cat, and most preferably human, but is not limited thereto. .
  • the treatment or administration method may be applied, oral or parenteral administration, and when administered parenterally, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine epidural injection, cerebrovascular injection or chest It can be administered by my injection.
  • HATU N-[(dimethylamino-)-1H-1,2,3-triazolo [4,5-b] pyridin-1-yl-methylene] -N-methylmethaneamini from the next step Fmoc amino acid Um hexafluorophosphate N-oxide) and 1-hydroxy-7-azabenzotriazole (HOAt) or HBTU (N-[(1H-benzotriazol-1-yl) (dimethylamino) methylene] -N-
  • the chain of peptides was extended by performing coupling using methylmethanealuminum hexafluorophosphate N-oxide) and DIEA (N, N-diisopropylethylamine) together with hydroxybenzotriazole (HOBt).
  • the crude peptide obtained by the above method was confirmed by using RP-HPLC (2996 Detector, 515 Pump, Waters) as a gradient solvent composition of acetonitrile and water containing 0.1% TFA, and confirming purity. As a result, less than 95% of the peptide was separated and purified by Prep-LC to obtain more than 97% of the peptide. As a result of elemental analysis with an elemental analyzer (EA1112, CE Instrument, Italy) to confirm the exact component of the peptide, it was confirmed that the content of each element of the peptide is identical to the content of each element obtained by calculating from the amino acid sequence. Did.
  • Adiponectin is also broken down into smaller units containing a globular domain, and subunits having a globular domain have a higher activity than adiponectin having a full length, and these receptors for adiponectin include adiponectin receptor 1 (AdipoR1).
  • AdipoR1 adiponectin receptor 1
  • adiponectin receptor 2 Crystal structures of the human adiponectin receptors. Nature. 2015 Apr 16; 520 (7547): 312-6. Doi: 10.1038 / nature14301).
  • the skin permeability of the adiponectin-derived peptide of the present invention prepared in Example 1 was most similar to that of human skin and was verified using pig skin, which is generally used for the permeability test.
  • FITC fluorescently attached peptide stock positive control 8-mer length peptide 2, 4-mer peptide 4
  • DMSO dimethyl sulfoxide
  • the adiponectin-derived peptide of the present invention was remarkably excellent in permeability to the skin as compared to a peptide having a length of 8 amino acids used as a control (FIG. 1).
  • Adiponectin acts by binding to adiponectin receptors, and when adiponectin receptors are activated, it is known to increase phosphorylation of AMPK, a lower signaling pathway, and activity of PPAR ⁇ / PPAR ⁇ (Adiponectin Receptor as a Key Player in Healthy Longevity and Obesity-Related Diseases) Cell metabolism.Volume 17, Issue 2, 5 February 2013, Pages 185-196). Accordingly, the phosphorylation of AMPK (promoting sub-ACC phosphorylation) and the activity of PPAR ⁇ / PPAR ⁇ were confirmed using the human muscle cell line RD cell line, which has been reported to be involved in the main etiology of sensitive skin.
  • the cells After culturing the human muscle cell line, RD cells, the cells were replaced with serum-free medium when the cells were 90% full. After treating the adiponectin-derived peptide and vehicle (normal control, CNT) of the present invention prepared in Example 1 and harvesting them after 24 hours, the proteins were separated, and the respective activity was measured using the corresponding assay kit and Western blot technique.
  • adiponectin-derived peptide and vehicle (normal control, CNT) of the present invention prepared in Example 1 and harvesting them after 24 hours, the proteins were separated, and the respective activity was measured using the corresponding assay kit and Western blot technique.
  • the adiponectin-derived peptide of the present invention induced an increase in the activity of PPAR ⁇ and PPAR ⁇ corresponding to proteins of the lower signaling pathway through activation of the adiponectin receptor in human muscle cell lines (FIGS. 2A and 2B), and also AMPK and ACC. It was confirmed that phosphorylation was induced (FIG. 2C).
  • Example 4 Adiponectin The effect of derived peptides on the action of sensitive skin-causing agents in human muscle cell lines
  • the RD cell line After culturing the human muscle cell line, the RD cell line, when the cells are 90% full, the cells are replaced with serum-free medium, and then the sensitive skin-inducing substance lactic acid (LA) 50 mM and the adiponectin peptide 5 ⁇ g of the present invention prepared in Example 1 / Ml, and after 4 hours, the cells were harvested and mRNA was extracted to observe the effect on the expression of the stimulatory receptors ASIC3 and TRPV1 and the neurotransmitter CGRP.
  • LA lactic acid
  • the adiponectin-derived peptide of the present invention can significantly suppress the expression of genes related to skin sensitivity caused by lactic acid (FIG. 3).
  • Example 5 Adiponectin Within protein Adiponectin Confirm the structure of peptides and the possibility of action through polymer formation in vivo
  • the three-dimensional structure of the adiponectin protein present in humans was analyzed to analyze the structural position of the adiponectin peptide prepared in the present invention and the possibility of adiponectin receptor action in vivo.
  • adiponectin peptide As a result, in the case of adiponectin peptide, it was found that a total of three times in the spherical domain known as the action site of the adiponectin protein were repeatedly present in the form of a trimer. Since it is distributed on the outer side, there is a high possibility that it can actually act on the adiponectin receptor. Particularly, in the case of the P5 peptide, it was confirmed that the peptide sequence repeated three times in the adiponectin protein formed a polymer when the three-dimensional protein structure was examined, and as a lipophilic amino acid inside the polymer and a hydrophilic amino acid outside the polymer. It can be confirmed that the possibility of acting on the adiponectin receptor by forming the polymer again when the hydrophilic substance is actually permeated into the human body (Fig. 4).
  • adiponectin peptide prepared in the present invention since it is a short amino acid sequence composed of 5-mer, there is a possibility that it overlaps with the amino acid sequence contained in other proteins actually present in the human body. In this case, it is difficult to see the sequence specifically present in adiponectin, and thus there is a problem that the likelihood of specifically acting on the adiponectin receptor decreases. Accordingly, a sequence overlapping with the adiponectin peptide sequence was searched among all protein sequences present in the human body using the UniProt database provided by NCBI.
  • the P5 peptide of the present invention was confirmed to exist only in the C1q complement protein superfamily to which the adiponectin protein belongs, and was confirmed to be a peptide sequence highly specific to the adiponectin protein.
  • the flexible lotion containing the adiponectin-derived peptide of the present invention as an active ingredient was prepared as shown in Table 2 below.
  • Raw material Content (parts by weight) Adiponectin-derived peptide of Example 1 10.00 1,3-butylene glycol 1.00 Disodium LED 0.05 Allantoin 0.10 Dipotassium glyceride 0.05 Citric Acid 0.01 Sodium citrate 0.02 Glyceres-26 1.00 Arbutin 2.00 Hydrogenated castor oil 1.00 ethanol 30.00 Preservative a very small amount coloring agent a very small amount Flavor a very small amount Purified water Balance
  • Raw material Content (parts by weight) Adiponectin-derived peptide of Example 1 10.0 1,3-butylene glycol 7.0 glycerin 1.0 D-panthenol 0.1 Plant extracts 3.2 Magnesium aluminum silicate 0.3 PEG-40 stearate 1.2 Stearic Acid 2.0 Polysorbate 60 1.5 Lipophilic glyceryl stearate 2.0 Sorbitan sesquioleate 1.5 Cetearyl alcohol 3.0 Mineral oil 4.0 Squalane 3.8 Carlylic / Capric Triglyceride 2.8 vegetable oil 1.8 Dimethicone 0.4 Dipotassium glyceride a very small amount Allantoin a very small amount Sodium hyaluronate a very small amount Tocopheryl Acetate Quantity Triethanolamine Quantity Preservative Quantity Flavor Quantity Purified water Balance
  • Raw material Content (parts by weight) Adiponectin-derived peptide of Example 1 3.5 Cetostearyl alcohol 1.6 Stearic acid 1.4 Lipophilic monostearate glycerin 1.8 PAGE-100 Stearate 2.6 Sesquiolein acid sorbitan 0.6 Squalene 4.8 Macadamia oil 2 Jojoba oil 2 Tocopherol acetate 0.4 Methyl polysiloxane 0.2 Echile Paraben 0.1 Tocopherol acetate 0.4 Methyl polysiloxane 0.2 Echile Paraben 0.1 Propyl paraben 0.1 1,3-butylene glycol 4 Methyl paraben 0.1 Shotgun 0.1 glycerin 4 d-pandenol 0.15 Allantoin 0.1 Carbomer (2% aq. Sol) 4 Triethanolamine 0.15 ethanol 3 pt 41891 0.1 p-H20 48.3
  • Adiponectin-derived peptide of the present invention ... 2 g
  • a powder was prepared by mixing the above components and filling the gas-tight fabric.
  • Adiponectin-derived peptide of the present invention ... 100 mg
  • tablets were prepared by tableting according to a conventional tablet manufacturing method.
  • Adiponectin-derived peptide of the present invention ... 100 mg
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • Adiponectin-derived peptide of the present invention ... 1 g
  • Adiponectin-derived peptide of the present invention ... 150 mg
  • Adiponectin-derived peptide of the present invention 10 ⁇ g / ml
  • the solution was filled in a 5 ml Type I ampoule made of transparent glass, sealed under an upper grid of air by dissolving the glass, and autoclaved at 120 ° C. for 15 minutes or more to sterilize to prepare an injection solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composition comprenant un fragment peptidique dérivé de l'adiponectine et, plus particulièrement, une composition cosmétique et une composition pharmaceutique pour la peau sensible comprenant comme principe actif au moins un peptide dérivé de l'adiponectine sélectionné dans le groupe constitué par les séquences d'acides aminés représentées par les séquences SEQ ID NO : 1 à SEQ ID NO : 21. Du fait que les peptides dérivés de l'adiponectine activent des voies de signalisation en aval des récepteurs de l'adiponectine dans des cellules musculaires impliquées dans la pathogenèse majeure de la peau sensible et inhibent également l'activité des récepteurs stimulateurs activés par des agents responsables de la peau sensible, la composition comprenant un peptide dérivé de l'adiponectine peut être utilisée efficacement pour empêcher ou soulager les symptômes de la peau sensible.
PCT/KR2018/010237 2018-09-03 2018-09-03 Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine WO2020050429A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/010237 WO2020050429A1 (fr) 2018-09-03 2018-09-03 Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/010237 WO2020050429A1 (fr) 2018-09-03 2018-09-03 Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine

Publications (1)

Publication Number Publication Date
WO2020050429A1 true WO2020050429A1 (fr) 2020-03-12

Family

ID=69721608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010237 WO2020050429A1 (fr) 2018-09-03 2018-09-03 Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine

Country Status (1)

Country Link
WO (1) WO2020050429A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314061B2 (en) * 2006-01-09 2012-11-20 Children's Hospital Medical Center Adiponectin for treatment of various disorders
KR20140096196A (ko) * 2013-01-10 2014-08-05 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 성장 억제 활성을 갖는 펩타이드를 포함하는 약학 및 화장료 조성물
KR20150032401A (ko) * 2013-09-17 2015-03-26 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
KR20180105902A (ko) * 2017-03-16 2018-10-01 서울대학교병원 아디포넥틴 유래 펩티드를 포함하는 민감성 피부용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314061B2 (en) * 2006-01-09 2012-11-20 Children's Hospital Medical Center Adiponectin for treatment of various disorders
KR20140096196A (ko) * 2013-01-10 2014-08-05 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 성장 억제 활성을 갖는 펩타이드를 포함하는 약학 및 화장료 조성물
KR20150032401A (ko) * 2013-09-17 2015-03-26 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
KR20180105902A (ko) * 2017-03-16 2018-10-01 서울대학교병원 아디포넥틴 유래 펩티드를 포함하는 민감성 피부용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, E. J. ET AL.: "Adiponectin deficiency contributes to sensitivity in human skin", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 135, no. 9, 2015, pages 2331 - 2334, XP055693003 *
OTVOS, L. ET AL.: "Design and development of a peptide-based adiponectin receptor agonist for cancer treatment", BMC BIOTECHNOLOGY, vol. 11, no. 90, 2011, pages 1 - 14, XP021110409, DOI: 10.1186/1472-6750-11-90 *

Similar Documents

Publication Publication Date Title
CN108056929B (zh) 一种抑制黑素生成的多肽组合物及应用
WO2015002393A1 (fr) Composition de traitement ou de prévention d'une maladie cutanée inflammatoire comprenant, comme ingrédient actif, un extrait d'agrumes immatures ou de la synéphrine, ou leur sel
KR101967630B1 (ko) 아디포넥틴 유래 펩티드 및 이를 포함하는 피부노화 방지 또는 피부주름 개선용 조성물
KR101915386B1 (ko) 아디포넥틴 유래 펩티드를 포함하는 민감성 피부용 조성물
KR20200080108A (ko) 근육 이완용 조성물
CN114933631A (zh) 肽衍生物异构体及其美容组合物或药物组合物和用途
WO2013137569A1 (fr) Tétrapeptide, et composition cosmétique contre le vieillissement et l'inflammation de la peau qui en comprend
WO2020050428A1 (fr) Composition favorisant la pousse des cheveux comprenant un peptide dérivé de l'adiponectine
EP4177259A1 (fr) Polypeptide permettant de réparer un dommage muqueux ou une plaie cutanée et son utilisation
WO2017116138A1 (fr) Peptide inhibiteur de la mélanine et composition le contenant
KR101915385B1 (ko) 아디포넥틴 유래 펩티드를 포함하는 발모 촉진용 조성물
WO2018034453A1 (fr) Conjugué de minoxidil et d'un peptide
WO2015034247A1 (fr) Composition contenant un composé de monoacétyldiacylglycérol comme principe actif pour prévenir ou traiter la dermatite atopique
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2020050429A1 (fr) Composition pour la peau sensible comprenant un peptide dérivé de l'adiponectine
WO2020050427A1 (fr) Peptide dérivé d'adiponectine et composition pour prévenir le vieillissement de la peau ou atténuer les rides de la peau le contenant
WO2017119756A1 (fr) Nouveau peptide fonctionnel anti-inflammatoire, blanchissant la peau, anti-âge et atténuant les rides, et composition contenant le peptide
US20230365643A1 (en) Peptide, and cosmetic composition and pharmaceutical composition comprising same
CN114805489A (zh) 一类用于修复皮肤损伤或黏膜损伤的多肽及其应用
WO2023018315A1 (fr) Composition cosmétique pour l'hydratation de la peau et l'apaisement de la peau comprenant un inhibiteur d'import nucléaire à perméabilité cellulaire améliorée
WO2023055056A1 (fr) Peptide comportant une activité de prévention de la chute des cheveux ou favorisant la croissance des cheveux, et son utilisation
WO2023055053A1 (fr) Peptide ayant une activité de prévention de la chute des cheveux ou de favorisation de la pousse des cheveux et son utilisation
WO2023055054A1 (fr) Peptide ayant une activité de prévention de la chute des cheveux ou d'activation de la pousse des cheveux, et utilisation associée
JP2007537140A (ja) 糖尿病における血中グルコースレベルを制御するテトラペプチド
WO2023055051A1 (fr) Peptide ayant une activité de prévention de la chute des cheveux ou de promotion de la pousse des cheveux, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18932417

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18932417

Country of ref document: EP

Kind code of ref document: A1